<table width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<col width="24%"></col>
<col width="76%"></col>
<tbody>
<tr>
<td colspan="2" stylecode="Rrule Botrule Lrule Toprule " valign="top">
<paragraph>
<content stylecode="bold">Benzodiazepines</content>
</paragraph>
</td>
</tr>
<tr>
<td align="right" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>There have been a number of reports regarding coma and death associated with the misuse and abuse of the combination of buprenorphine and benzodiazepines. In many, but not all of these cases, buprenorphine was misused by self-injection of crushed buprenorphine tablets. Preclinical studies have shown that the combination of benzodiazepines and buprenorphine altered the usual ceiling effect on buprenorphine-induced respiratory depression, making the respiratory effects of buprenorphine appear similar to those of full opioid agonists.</paragraph>
</td>
</tr>
<tr>
<td align="right" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>Closely monitor patients with concurrent use of buprenorphine sublingual tablets and benzodiazepines. Warn patients that it is extremely dangerous to self-administer benzodiazepines while taking buprenorphine sublingual tablets, and warn patients to use benzodiazepines concurrently with buprenorphine sublingual tablets only as directed by their healthcare provider.</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Non-Benzodiazepine Central Nervous System (CNS) Depressants</content>
</paragraph>
</td>
</tr>
<tr>
<td align="right" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>Due to additive pharmacologic effect, the concomitant use of non-benzodiazepine CNS depressants, including alcohol, can increase the risk of hypotension, respiratory depression, profound sedation, coma, and death.</paragraph>
</td>
</tr>
<tr>
<td align="right" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients closely for signs of respiratory depression and sedation <content stylecode="italics">[see Warnings and Precautions (<linkhtml href="#i4i_section_id_7cc1e040-a05d-48e7-bfa9-12351ee194cc">5.2</linkhtml>, <linkhtml href="#i4i_section_id_cb1dc0b4-2833-40ad-b55b-683b0aba6f96">5.3</linkhtml>)]</content>.</paragraph>
</td>
</tr>
<tr>
<td align="right" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Examples:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>Alcohol, non-benzodiazepine sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, and other opioids.</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Inhibitors of CYP3A4</content>
</paragraph>
</td>
</tr>
<tr>
<td align="right" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>The concomitant use of buprenorphine and CYP3A4 inhibitors can increase the plasma concentration of buprenorphine, resulting in increased or prolonged opioid effects, particularly when an inhibitor is added after a stable dose of buprenorphine sublingual tablets is achieved. </paragraph>
<paragraph>After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, the buprenorphine plasma concentration will decrease <content stylecode="italics">[see Clinical Pharmacology (<linkhtml href="#i4i_pharmacokinetics_id_fa3f2f22-4dde-4a6d-96e7-27fd4e4a7b72">12.3</linkhtml>)]</content>, potentially resulting in decreased opioid efficacy or a withdrawal syndrome in patients who had developed physical dependence to buprenorphine.</paragraph>
</td>
</tr>
<tr>
<td align="right" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>If concomitant use is necessary, consider dosage reduction of buprenorphine sublingual tablets until stable drug effects are achieved. Monitor patients for respiratory depression and sedation at frequent intervals.</paragraph>
<paragraph>If a CYP3A4 inhibitor is discontinued, consider increasing the buprenorphine sublingual tablet dosage until stable drug effects are achieved. Monitor for signs of opioid withdrawal.</paragraph>
</td>
</tr>
<tr>
<td align="right" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Examples:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>Macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), protease inhibitors (e.g., ritonavir)</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">CYP3A4 Inducers</content>
</paragraph>
</td>
</tr>
<tr>
<td align="right" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>The concomitant use of buprenorphine and CYP3A4 inducers can decrease the plasma concentration of buprenorphine <content stylecode="italics">[see Clinical Pharmacology (<linkhtml href="#i4i_pharmacokinetics_id_fa3f2f22-4dde-4a6d-96e7-27fd4e4a7b72">12.3</linkhtml>)]</content>, potentially resulting in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence to buprenorphine. </paragraph>
<paragraph>After stopping a CYP3A4 inducer, as the effects of the inducer decline, the buprenorphine plasma concentration will increase <content stylecode="italics">[see Clinical Pharmacology (<linkhtml href="#i4i_pharmacokinetics_id_fa3f2f22-4dde-4a6d-96e7-27fd4e4a7b72">12.3</linkhtml>)]</content>, which could increase or prolong both therapeutic effects and adverse reactions and may cause serious respiratory depression.</paragraph>
</td>
</tr>
<tr>
<td align="right" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>If concomitant use is necessary, consider increasing the buprenorphine sublingual tablets dosage until stable drug effects are achieved. Monitor for signs of opioid withdrawal. </paragraph>
<paragraph>If a CYP3A4 inducer is discontinued, consider buprenorphine sublingual tablets dosage reduction and monitor for signs of respiratory depression.</paragraph>
</td>
</tr>
<tr>
<td align="right" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Examples:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>Rifampin, carbamazepine, phenytoin</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Antiretrovirals: Non-nucleoside reverse transcriptase inhibitors (NNRTIs)</content>
</paragraph>
</td>
</tr>
<tr>
<td align="right" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are metabolized principally by CYP3A4. Efavirenz, nevirapine, and etravirine are known CYP3A inducers, whereas delaviridine is a CYP3A inhibitor. Significant pharmacokinetic interactions between NNRTIs (e.g., efavirenz and delavirdine) and buprenorphine have been shown in clinical studies, but these pharmacokinetic interactions did not result in any significant pharmacodynamic effects.</paragraph>
</td>
</tr>
<tr>
<td align="right" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>Patients who are on chronic buprenorphine sublingual tablets treatment should have their dose monitored if NNRTIs are added to their treatment regimen.</paragraph>
</td>
</tr>
<tr>
<td align="right" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Examples:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>efavirenz, nevirapine, etravirine, delavirdine</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Antiretrovirals: Protease inhibitors (PIs)</content>
</paragraph>
</td>
</tr>
<tr>
<td align="right" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>Studies have shown some antiretroviral protease inhibitors (PIs) with CYP3A4 inhibitory activity (nelfinavir, lopinavir/ritonavir, ritonavir) have little effect on buprenorphine pharmacokinetic and no significant pharmacodynamic effects. Other PIs with CYP3A4 inhibitory activity (atazanavir and atazanavir/ritonavir) resulted in elevated levels of buprenorphine and norbuprenorphine, and patients in one study reported increased sedation. Symptoms of opioid excess have been found in post-marketing reports of patients receiving buprenorphine and atazanavir with and without ritonavir concomitantly.</paragraph>
</td>
</tr>
<tr>
<td align="right" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>Monitor patients taking buprenorphine sublingual tablets and atazanavir with and without ritonavir, and reduce dose of buprenorphine sublingual tablets if warranted.</paragraph>
</td>
</tr>
<tr>
<td align="right" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Examples:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>atazanavir, ritonavir</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Antiretrovirals: Nucleoside reverse transcriptase inhibitors (NRTIs)</content>
</paragraph>
</td>
</tr>
<tr>
<td align="right" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>Nucleoside reverse transcriptase inhibitors (NRTIs) do not appear to induce or inhibit the P450 enzyme pathway, thus no interactions with buprenorphine are expected.</paragraph>
</td>
</tr>
<tr>
<td align="right" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>None</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Serotonergic Drugs</content>
</paragraph>
</td>
</tr>
<tr>
<td align="right" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>The concomitant use of opioids with other drugs that affect the serotonergic</paragraph>
<paragraph>neurotransmitter system has resulted in serotonin syndrome<content stylecode="italics">.</content>
</paragraph>
</td>
</tr>
<tr>
<td align="right" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>If concomitant use is warranted, carefully observe the patient, particularly during</paragraph>
<paragraph>treatment initiation and dose adjustment. Discontinue buprenorphine sublingual tablets if serotonin syndrome is suspected.</paragraph>
</td>
</tr>
<tr>
<td align="right" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Examples:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine</paragraph>
<paragraph>reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3</paragraph>
<paragraph>receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g.,</paragraph>
<paragraph>mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Monoamine Oxidase Inhibitors (MAOIs)</content>
</paragraph>
</td>
</tr>
<tr>
<td align="right" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>MAOI interactions with opioids may manifest as serotonin syndrome or opioid toxicity (e.g., respiratory depression, coma).</paragraph>
</td>
</tr>
<tr>
<td align="right" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>The use of buprenorphine sublingual tablets is not recommended for patients taking MAOIs or within 14 days of stopping such treatment.</paragraph>
</td>
</tr>
<tr>
<td align="right" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Examples:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>phenelzine, tranylcypromine, linezolid</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Muscle Relaxants</content>
</paragraph>
</td>
</tr>
<tr>
<td align="right" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>Buprenorphine may enhance the neuromuscular blocking action of skeletal muscle</paragraph>
<paragraph>relaxants and produce an increased degree of respiratory depression.</paragraph>
</td>
</tr>
<tr>
<td align="right" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>Monitor patients receiving muscle relaxants and buprenorphine sublingual tablets for signs of respiratory depression that may be greater than otherwise expected and decrease the dosage of buprenorphine sublingual tablets and/or the muscle relaxant as necessary.</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Diuretics</content>
</paragraph>
</td>
</tr>
<tr>
<td align="right" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone.</paragraph>
</td>
</tr>
<tr>
<td align="right" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>Monitor patients for signs of diminished diuresis and/or effects on blood pressure</paragraph>
<paragraph>and increase the dosage of the diuretic as needed.</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Anticholinergic Drugs</content>
</paragraph>
</td>
</tr>
<tr>
<td align="right" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus.</paragraph>
</td>
</tr>
<tr>
<td align="right" stylecode="Rrule Botrule Lrule Toprule " valign="top">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="Rrule Botrule Lrule Toprule " valign="top">
<paragraph>Monitor patients for signs of urinary retention or reduced gastric motility when</paragraph>
<paragraph>buprenorphine sublingual tablets are used concomitantly with anticholinergic drugs.</paragraph>
</td>
</tr>
</tbody>
</table>